JPWO2021041989A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021041989A5
JPWO2021041989A5 JP2022513477A JP2022513477A JPWO2021041989A5 JP WO2021041989 A5 JPWO2021041989 A5 JP WO2021041989A5 JP 2022513477 A JP2022513477 A JP 2022513477A JP 2022513477 A JP2022513477 A JP 2022513477A JP WO2021041989 A5 JPWO2021041989 A5 JP WO2021041989A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
days
treating
single dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545553A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048635 external-priority patent/WO2021041989A1/en
Publication of JP2022545553A publication Critical patent/JP2022545553A/ja
Publication of JPWO2021041989A5 publication Critical patent/JPWO2021041989A5/ja
Pending legal-status Critical Current

Links

JP2022513477A 2019-08-29 2020-08-28 A型インフルエンザ感染の治療のための組成物及び方法 Pending JP2022545553A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962893747P 2019-08-29 2019-08-29
US62/893,747 2019-08-29
US202062993519P 2020-03-23 2020-03-23
US62/993,519 2020-03-23
US202063040966P 2020-06-18 2020-06-18
US63/040,966 2020-06-18
PCT/US2020/048635 WO2021041989A1 (en) 2019-08-29 2020-08-28 Compositions and methods for treatment of influenza a infection

Publications (2)

Publication Number Publication Date
JP2022545553A JP2022545553A (ja) 2022-10-27
JPWO2021041989A5 true JPWO2021041989A5 (zh) 2023-09-04

Family

ID=72473986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513477A Pending JP2022545553A (ja) 2019-08-29 2020-08-28 A型インフルエンザ感染の治療のための組成物及び方法

Country Status (11)

Country Link
US (1) US20220306728A1 (zh)
EP (1) EP4021502A1 (zh)
JP (1) JP2022545553A (zh)
KR (1) KR20220061999A (zh)
CN (1) CN115052630A (zh)
AU (1) AU2020335922A1 (zh)
BR (1) BR112022003529A2 (zh)
CA (1) CA3148990A1 (zh)
IL (1) IL290752A (zh)
MX (1) MX2022002447A (zh)
WO (1) WO2021041989A1 (zh)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US9347043B2 (en) 2008-10-22 2016-05-24 Institute For Research In Biomedicine Methods for producing antibodies from plasma cells
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
SG11201805001UA (en) * 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a

Similar Documents

Publication Publication Date Title
JP3280675B2 (ja) 多価dtpポリオワクチン
JP2505944B2 (ja) (S)―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
JP5781606B2 (ja) インフルエンザ、一般的な感冒および炎症の治療におけるレボセチリジンおよびモンテルカストの使用
KR20170044211A (ko) 항체 제제
ES2267591T3 (es) Combinaciones farmaceuticas que comprenden un antagonista del receptor p2t y melagatran.
JP2020073566A5 (zh)
KR100333113B1 (ko) 헬리코박터피롤리관련위십이지장질환의치료방법
JP2019537555A5 (zh)
JP2016512262A (ja) 血管炎の処置におけるレボセチリジン及びモンテルカストの使用
JP2014501718A (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
JP2020500864A5 (zh)
JP2023523248A (ja) 顆粒球マクロファージコロニー刺激因子に基づく感染治療
KR20230038644A (ko) 코로나바이러스 치료를 위한 피르페니돈
JP2022501358A (ja) Hivの予防のためのインテグラーゼ阻害剤
US7132453B2 (en) Method of using prostacyclin to treat respiratory syncytial virus infections
US11666617B2 (en) Treatment of warts
JPWO2021041989A5 (zh)
WO2014059363A1 (en) Oral solution formulations of aripiprazole
JP2003171266A (ja) キシリトールを含有する解熱性調剤
CA3176432A1 (en) Preventative treatment of migraine
JP7417339B1 (ja) アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療
JP2012025734A (ja) 骨髄異形性症候群を治療するための組成物および方法
US20220362190A1 (en) Viral inactivation spray and gargling formulation
RU2678981C2 (ru) Композиция от бешенства, содержащая адъювант pika
CA3205325A1 (en) Method for producing blood plasma product useful in the treatment of viral infections characterized by an uncontrolled release of proinflammatory cytokines